Company Filing History:
Years Active: 1987-2000
Title: Michael R. Ostrander: Innovator in Viral Infection Treatment
Introduction
Michael R. Ostrander is a notable inventor based in Glen Ridge, NJ (US). He has made significant contributions to the field of virology, particularly in the treatment of RNA viral infections. With a total of 3 patents, his work has the potential to impact both human and animal health.
Latest Patents
Ostrander's latest patents include a method for treating RNA viral infections using RNA chain terminators. This invention focuses on controlling and treating RNA-replicating viral infections that affect humans, animals, and plants. The RNA chain-terminating agents, such as 3'-deoxyribouracil, 3'-deoxyriboguanine, and 3'-deoxyribocytosine, are highlighted as effective treatments. Another significant patent involves a method for treating herpes viral infections using HBNF and MK proteins. This method aims to inhibit the infectivity of viruses characterized by the presence of a heparin-binding protein. The pharmaceutical compositions containing HBNF and MK proteins are designed to prevent or treat viral infections effectively.
Career Highlights
Throughout his career, Michael R. Ostrander has worked with prominent companies such as American Cyanamid Company and Schering Corporation. His experience in these organizations has contributed to his expertise in the field of virology and pharmaceutical development.
Collaborations
Ostrander has collaborated with notable colleagues, including Tattanahali L. Nagabhushan and George H. Miller. These partnerships have likely enhanced his research and development efforts in the treatment of viral infections.
Conclusion
Michael R. Ostrander's innovative work in the treatment of viral infections showcases his dedication to advancing medical science. His patents reflect a commitment to finding effective solutions for challenging health issues.